Expression of cancer-testis antigens in hepatocellular carcinoma

Table 2 Expression of CT antigens and clinico pathological indicators

Group	n1	MAGE-1		SSX-1		CTp11		HCA587		CT2(+)
		+	-	+	-	+	-	+	-	+	-
Total number	105	79	26	76	29	66	39	59	46	98	7
Gender
Male	90	70	20	66	24	57	33	48	42	85	5
Female	15	9	6	10	5	9	6	11	4	13	2
Tumor diameter
≤ 5 cm	26	18	8	16	10	14	12	15	11	22	4
> 5 cm	79	61	18	60	19	52	27	44	35	76	3
TNM stage
I + II	43	29	14	31	12	27	16	22	21	39	4
III + IV	62	50	12	45	17	39	23	37	25	59	3
Hepatitis B virus
HBV (+)	98	74	24	71	27	62	36	55	43	91	7
HBV (-)	7	5	2	5	2	4	3	4	3	7	0
Hepatitis C virus
HCV (+)	5	5	0	4	1	4	1	4	1	5	0
HCV (-)	100	74	26	72	28	62	38	55	45	93	7
AFP (ng/mL)
< 40	35	28	7	22	13	20	15	18	17	32	3
≥ 40	70	51	19	54	16	46	24	41	29	66	4
Differentiation
Well	18	13	5	12	6	12	6	9	9	16	2
Moderately	61	44	17	44	17	39	22	34	27	58	3
Poorly	26	22	4	20	6	15	11	16	10	24	2

n¹: Number of samples; CT²: At least one of these 4 CT antigen genes; No relationship is found between the expression of CT antigens and clinical indicators such as age, gender, degree of tumour differentiation, serum α-FP level, TNM classification, tumor size, infection of hepatitis B virus or hepatitis C virus (P > 0.05).